Charles Schwab Investment Management Inc. Has $29.23 Million Position in Axonics, Inc. (NASDAQ:AXNX)

Charles Schwab Investment Management Inc. grew its holdings in Axonics, Inc. (NASDAQ:AXNX) by 1.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 419,985 shares of the company’s stock after purchasing an additional 6,115 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.82% of Axonics worth $29,231,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC lifted its stake in shares of Axonics by 0.9% during the second quarter. AQR Capital Management LLC now owns 18,337 shares of the company’s stock valued at $1,233,000 after acquiring an additional 161 shares during the period. Xponance Inc. lifted its stake in shares of Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after acquiring an additional 225 shares during the period. Arizona State Retirement System lifted its stake in shares of Axonics by 2.5% during the second quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock valued at $960,000 after acquiring an additional 355 shares during the period. Mercer Global Advisors Inc. ADV lifted its stake in shares of Axonics by 12.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock valued at $469,000 after acquiring an additional 785 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Axonics by 4.7% during the second quarter. The Manufacturers Life Insurance Company now owns 21,485 shares of the company’s stock valued at $1,444,000 after acquiring an additional 974 shares during the period. Institutional investors and hedge funds own 99.48% of the company’s stock.

Insider Activity at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares in the company, valued at $2,801,526.42. This represents a 6.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Friday, November 8th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat, Axonics currently has a consensus rating of “Hold” and an average target price of $71.00.

Axonics Trading Up 0.8 %

NASDAQ AXNX opened at $70.98 on Thursday. The stock has a 50-day simple moving average of $70.38 and a 200 day simple moving average of $68.91. The company has a market capitalization of $3.63 billion, a PE ratio of -591.45 and a beta of 0.82. Axonics, Inc. has a 12 month low of $55.09 and a 12 month high of $71.05.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.